Artículos de revistas
Skin and oral lesions associated to imatinib mesylate therapy
Fecha
2009Registro en:
SUPPORTIVE CARE IN CANCER, v.17, n.4, p.465-468, 2009
0941-4355
10.1007/s00520-008-0536-8
Autor
BASSO, Fernanda Goncalves
BOER, Camila Cominato
CORREA, Maria Elvira Pizzigatti
TORREZAN, Marcia
CINTRA, Maria Leticia
MAGALHAES, Marina H. C. Gallottini de
SANTOS, Paulo da Silva
SOUZA, Carmino Antonio de
Institución
Resumen
Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph(+) in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.